[Osteoporosis therapy compared. More solid bones with bisphosphonates].
D019386:Alendronate / Q000008:administration & dosage / Q000627:therapeutic use*; D015519:Bone Density; D002986:Clinical Trials as Topic; D004164:Diphosphonates / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D050723:Fractures, Bone / Q000517:prevention & control; D006801:Humans; D015201:Meta-Analysis as Topic; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000188:drug therapy*; D020849:Raloxifene Hydrochloride / Q000008:administration & dosage / Q000627:therapeutic use*; D020845:Selective Estrogen Receptor Modulators / Q000008:administration & dosage / Q000627:therapeutic use*; D016103:Spinal Fractures / Q000517:prevention & control; D013997:Time Factors
D004164:Diphosphonates; D020845:Selective Estrogen Receptor Modulators; D020849:Raloxifene Hydrochloride; D019386:Alendronate